NCT02525692Phase 2Terminated

Oral ONC201 in Adult Recurrent Glioblastoma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-04-17Actual

Enrollment · participants84Actual

Source updated2024-12-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Glioblastoma; Diffuse Midline Glioma; H3 K27M Glioma; Thalamic Glioma; Infratentorial Glioma; Basal Ganglia Glioma

Treatments or interventions studied

Dordaviprone (ONC201)DrugAlso known as Dordaviprone

Primary outcomes · main study measures

measure: Percent of Patients With Probability of Progression-Free Survival at 6 Months; description: Progression-free survival rate at 6 months was defined as the percentage of patients who exhibit progression-free survival for \>6 months.; timeFrame: Progression-free survival assessments were conducted 6 months following treatment initiation.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history